{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:00:41Z","timestamp":1782230441850,"version":"3.54.5"},"posted":{"date-parts":[[2021,12,23]]},"group-title":"Microbiology","reference-count":24,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,12,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>The rapid spread of the highly contagious Omicron variant of SARS-CoV-2 along with its high number of mutations in the spike gene has raised alarm about the effectiveness of current medical countermeasures. To address this concern, we measured neutralizing antibodies against Omicron in three important settings: (1) post-vaccination sera after two and three immunizations with the Pfizer\/BNT162b2 vaccine, (2) convalescent sera from unvaccinated individuals infected by different variants, and (3) clinical-stage therapeutic antibodies. Using a pseudovirus neutralization assay, we found that titers against Omicron were low or undetectable after two immunizations and in most convalescent sera. A booster vaccination significantly increased titers against Omicron to levels comparable to those seen against the ancestral (D614G) variant after two immunizations. Neither age nor sex were associated with differences in post-vaccination antibody responses. Only three of 24 therapeutic antibodies tested retained their full potency against Omicron and high-level resistance was seen against fifteen. These findings underscore the potential benefit of booster mRNA vaccines for protection against Omicron and the need for additional therapeutic antibodies that are more robust to highly mutated variants.<\/jats:p>\n                <jats:sec>\n                  <jats:title>One Sentence Summary<\/jats:title>\n                  <jats:p>Third dose of Pfizer\/BioNTech COVID-19 vaccine significantly boosts neutralizing antibodies to the Omicron variant compared to a second dose, while neutralization of Omicron by convalescent sera, two-dose vaccine-elicited sera, or therapeutic antibodies is variable and often low.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2021.12.22.473880","type":"posted-content","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T23:50:10Z","timestamp":1640303410000},"source":"Crossref","is-referenced-by-count":22,"title":["SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster"],"prefix":"10.64898","author":[{"given":"Sabrina","family":"Lusvarghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon D.","family":"Pollett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabari Nath","family":"Neerukonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Vassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusrat J.","family":"Epsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C","family":"Fries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5114-1669","authenticated-orcid":false,"given":"Brian K","family":"Agan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lindholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupal","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan C.","family":"Ewers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahaniyat","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Goguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Hollis-Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si\u2019Ana A.","family":"Coggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah C.","family":"Katzelnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Tribble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Eakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl J.","family":"Erlandson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Laing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy H.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Mitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol D.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2022010300551048000_2021.12.22.473880v2.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.05.005"},{"key":"2022010300551048000_2021.12.22.473880v2.2","doi-asserted-by":"crossref","unstructured":"Y. Cao , J. Wang , F. Jian , T. Xiao , W. Song , A. Yisimayi , W. Huang , Q. Li , P. Wang , R. An , J. Wang , Y. Wang , X. Niu , S. Yang , H. Liang , H. Sun , T. Li , Y. Yu , Q. Cui , S. Liu , X. Yang , S. Du , Z. Zhang , X. Hao , F. Shao , R. Jin , X. Wang , J. Xiao , Y. Wang , X. S. Xie , B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. bioRxiv, 2021.2012.2007.470392 (2021).","DOI":"10.1101\/2021.12.07.470392"},{"key":"2022010300551048000_2021.12.22.473880v2.3","doi-asserted-by":"crossref","unstructured":"A. R\u00f6ssler , L. Riepler , D. Bante , D. v. Laer , J. Kimpel , SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals. medRxiv, 2021.2012.2008.21267491 (2021).","DOI":"10.1101\/2021.12.08.21267491"},{"key":"2022010300551048000_2021.12.22.473880v2.4","doi-asserted-by":"crossref","unstructured":"L. Lu , B. W.-Y. Mok , L. Chen , J. M.-C. Chan , O. T.-Y. Tsang , B. H.-S. Lam , V. W.-M. Chuang , A. W.-H. Chu , W.-M. Chan , J. D. Ip , B. P.-C. Chan , R. Zhang , C. C.-Y. Yip , V. C.-C. Cheng , K.-H. Chan , I. F.-N. Hung , K.-Y. Yuen , H. Chen , K. K.-W. To , Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. medRxiv, 2021.2012.2013.21267668 (2021).","DOI":"10.1101\/2021.12.13.21267668"},{"key":"2022010300551048000_2021.12.22.473880v2.5","doi-asserted-by":"crossref","unstructured":"N. Ikemura , A. Hoshino , Y. Higuchi , S. Taminishi , T. Inaba , S. Matoba , SARS-CoV-2 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal antibodies. medRxiv, 2021.2012.2013.21267761 (2021).","DOI":"10.1101\/2021.12.13.21267761"},{"key":"2022010300551048000_2021.12.22.473880v2.6","doi-asserted-by":"crossref","unstructured":"E. Cameroni , C. Saliba , J. E. Bowen , L. E. Rosen , K. Culap , D. Pinto , A. De Marco , S. K. Zepeda , J. di Iulio , F. Zatta , H. Kaiser , J. Noack , N. Farhat , N. Czudnochowski , C. Havenar-Daughton , K. R. Sprouse , J. R. Dillen , A. E. Powell , A. Chen , C. Maher , L. Yin , D. Sun , L. Soriaga , C. Gustafsson , H. Chu , N. M. Franko , J. Logue , N. T. Iqbal , I. Mazzitelli , J. Geffner , R. Grifantini , A. Gori , A. Riva , O. Giannini , A. Ceschi , P. Ferrari , A. Franzetti-Pellanda , C. Garzoni , C. Hebner , L. Purcell , L. Piccoli , M. S. Pizzuto , A. C. Walls , A. Telenti , H. W. Virgin , A. Lanzavecchia , D. Veesler , G. Snell , D. Corti , Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv, 2021.2012.2012.472269 (2021).","DOI":"10.1038\/d41586-021-03825-4"},{"key":"2022010300551048000_2021.12.22.473880v2.7","doi-asserted-by":"crossref","unstructured":"S. Cele , L. Jackson , K. Khan , D. Khoury , T. Moyo-Gwete , H. Tegally , C. Scheepers , D. Amoako , F. Karim , M. Bernstein , G. Lustig , D. Archary , M. Smith , Y. Ganga , Z. Jule , K. Reedoy , J. E. San , S.-H. Hwa , J. Giandhari , J. M. Blackburn , B. I. Gosnell , S. A. Karim , W. Hanekom , NGS-SA, C.-K. Team , A. von Gottberg , J. Bhiman , R. J. Lessells , M.-Y. S. Moosa , M. Davenport , T. de Oliveira , P. L. Moore , A. Sigal , SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv, 2021.2012.2008.21267417 (2021).","DOI":"10.1101\/2021.12.08.21267417"},{"key":"2022010300551048000_2021.12.22.473880v2.8","doi-asserted-by":"crossref","unstructured":"C. I. Kaku , E. R. Champney , J. Normark , C. E. Johnson , C. Ahlm , M. Sakharkar , M. E. Ackerman , M. N. E. Forsell , L. M. Walker , Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1\/mRNA-1273 prime-boost vaccination. medRxiv, 2021.2012.2013.21267598 (2021).","DOI":"10.1101\/2021.12.13.21267598"},{"key":"2022010300551048000_2021.12.22.473880v2.9","doi-asserted-by":"crossref","unstructured":"W. F. Garcia-Beltran , K. J. St Denis , A. Hoelzemer , E. C. Lam , A. D. Nitido , M. L. Sheehan , C. Berrios , O. Ofoman , C. C. Chang , B. M. Hauser , J. Feldman , D. J. Gregory , M. C. Poznansky , A. G. Schmidt , A. J. Iafrate , V. Naranbhai , A. B. Balazs , mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. medRxiv, 2021.2012.2014.21267755 (2021).","DOI":"10.2139\/ssrn.3985605"},{"key":"2022010300551048000_2021.12.22.473880v2.10","doi-asserted-by":"crossref","unstructured":"H. Gruell , K. Vanshylla , P. Tober-Lau , D. Hillus , P. Schommers , C. Lehmann , F. Kurth , L. E. Sander , F. Klein , mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. medRxiv, 2021.2012.2014.21267769 (2021).","DOI":"10.21203\/rs.3.rs-1168453\/v1"},{"key":"2022010300551048000_2021.12.22.473880v2.11","doi-asserted-by":"crossref","unstructured":"F. Schmidt , F. Muecksch , Y. Weisblum , J. D. Silva , E. Bednarski , A. Cho , Z. Wang , C. Gaebler , M. Caskey , M. C. Nussenzweig , T. Hatziioannou , P. D. Bieniasz , Plasma neutralization properties of the SARS-CoV-2 Omicron variant. medRxiv, 2021.2012.2012.21267646 (2021).","DOI":"10.1101\/2021.12.12.21267646"},{"key":"2022010300551048000_2021.12.22.473880v2.12","doi-asserted-by":"crossref","unstructured":"K. Basile , R. J. Rockett , K. McPhie , M. Fennell , J. Johnson-Mackinnon , J. E. Agius , W. Fong , H. Rahman , D. Ko , L. Donavan , L. Hueston , C. Lam , A. Arnott , S. C.-A. Chen , S. Maddocks , M. V. O\u2019Sullivan , D. E. Dwyer , V. Sintchenko , J. Kok , Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. bioRxiv, 2021.2012.2012.472252 (2021).","DOI":"10.1101\/2021.12.12.472252"},{"key":"2022010300551048000_2021.12.22.473880v2.13","doi-asserted-by":"crossref","unstructured":"I. Nemet , L. Kliker , Y. Lustig , N. S. Zuckerman , O. Erster , C. Cohen , Y. Kreiss , S. Alroy-Preis , G. Regev-Yochay , E. Mendelson , M. Mandelboim , Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. medRxiv, 2021.2012.2013.21267670 (2021).","DOI":"10.1101\/2021.12.13.21267670"},{"key":"2022010300551048000_2021.12.22.473880v2.14","doi-asserted-by":"crossref","unstructured":"A. Wilhelm , M. Widera , K. Grikscheit , T. Toptan , B. Schenk , C. Pallas , M. Metzler , N. Kohmer , S. Hoehl , F. A. Helfritz , T. Wolf , U. Goetsch , S. Ciesek , Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. medRxiv, 2021.2012.2007.21267432 (2021).","DOI":"10.1101\/2021.12.07.21267432"},{"key":"2022010300551048000_2021.12.22.473880v2.15","doi-asserted-by":"crossref","unstructured":"N. Doria-Rose , X. Shen , S. D. Schmidt , S. O\u2019Dell , C. McDanal , W. Feng , J. Tong , A. Eaton , M. Maglinao , H. Tang , R. L. Atmar , K. E. Lyke , L. Wang , y. Zhang , M. R. Gaudinski , W. P. Black , I. Gordon , M. Guech , J. E. Ledgerwood , J. N. Misasi , A. Widge , P. C. Roberts , J. Beigel , B. Korber , R. Pajon , J. R. Mascola , D. C. Montefiori , Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies. medRxiv, 2021.2012.2015.21267805 (2021).","DOI":"10.1101\/2021.12.15.21267805"},{"key":"2022010300551048000_2021.12.22.473880v2.16","doi-asserted-by":"crossref","unstructured":"J. M. Carre\u00f1o , H. Alshammary , J. Tcheou , G. Singh , A. Raskin , H. Kawabata , L. Sominsky , J. Clark , D. C. Adelsberg , D. Bielak , A. S. Gonzalez-Reiche , P. P. S. Group , K. Srivastava , E. M. Sordillo , G. Bajic , H. van Bakel , V. Simon , F. Krammer , Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate. medRxiv, 2021.2012.2020.21268134 (2021).","DOI":"10.1101\/2021.12.20.21268134"},{"key":"2022010300551048000_2021.12.22.473880v2.17","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12879-021-06233-1","article-title":"Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers","volume":"21","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2022010300551048000_2021.12.22.473880v2.18","doi-asserted-by":"crossref","unstructured":"E. D. Laing , C. D. Weiss , E. C. Samuels , S. A. A. Coggins , W. Wang , R. Wang , R. Vassell , S. L. Sterling , M. A. Tso , T. Conner , E. Goguet , M. Moser , B. M. Jackson-Thompson , L. Illinik , J. Davies , O. Ortega , E. Parmelee , M. Hollis-Perry , S. E. Maiolatesi , G. Wang , K. F. Ramsey , A. E. Reyes , Y. Alcorta , M. A. Wong , A. R. Lindrose , C. A. Duplessis , D. R. Tribble , A. M. W. Malloy , T. H. Burgess , S. D. Pollett , C. H. Olsen , C. C. Broder , E. Mitre , Durability of antibody responses and frequency of clinical and subclinical SARS-CoV-2 infection six months after BNT162b2 COVID-19 vaccination in healthcare workers. medRxiv, 2021.2010.2016.21265087 (2021).","DOI":"10.1101\/2021.10.16.21265087"},{"key":"2022010300551048000_2021.12.22.473880v2.19","doi-asserted-by":"crossref","first-page":"ofab556","DOI":"10.1093\/ofid\/ofab556","article-title":"COVID-19 Outcomes Among US Military Health System Beneficiaries Include Complications Across Multiple Organ Systems and Substantial Functional Impairment","volume":"8","author":"E. C.-C. S. Group","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022010300551048000_2021.12.22.473880v2.20","doi-asserted-by":"crossref","unstructured":"S. Lusvarghi , W. Wang , R. Herrup , S. N. Neerukonda , R. Vassell , L. Bentley , A. E. Eakin , K. J. Erlandson , C. D. Weiss , Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects. J Virol, JVI0111021 (2021).","DOI":"10.1101\/2021.07.16.452748"},{"key":"2022010300551048000_2021.12.22.473880v2.21","doi-asserted-by":"crossref","unstructured":"M. Schubert , F. Bertoglio , S. Steinke , P. A. Heine , M. A. Ynga-Durand , F. Zuo , L. Du , J. Korn , M. Milo\u0161evi\u0107 , E. V. Wenzel , H. Maass , F. Krstanovi\u0107 , S. Polten , M. Pribani\u0107-Mate\u0161i\u0107 , I. Brizi\u0107 , A. Piralla , F. Baldanti , L. Hammarstr\u00f6m , S. D\u00fcbel , A. \u0160usti\u0107 , H. Marcotte , M. Strengert , A. Proti\u0107 , Q. Pan Hammarstr\u00f6m , L. \u010cicin-\u0160ain , M. Hust , Human serum from SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant in comparison to the original Wuhan strain and the Beta and Delta variants. medRxiv, 2021.2012.2010.21267523 (2021).","DOI":"10.1101\/2021.12.10.21267523"},{"key":"2022010300551048000_2021.12.22.473880v2.22","doi-asserted-by":"crossref","unstructured":"E. D. Laing , S. L. Sterling , S. A. Richard , N. J. Epsi , S. Coggins , E. C. Samuels , S. Phogat , L. Yan , N. Moreno , C. L. Coles , M. Drew , J. Mehalko , S. Merritt , K. Mende , V. Munster , E. de Wit , K. K. Chung , E. V. Millar , D. R. Tribble , M. P. Simons , S. D. Pollett , D. Esposito , C. Lanteri , G. T. Clifton , E. Mitre , T. H. Burgess , C. C. Broder , Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses. medRxiv, (2021).","DOI":"10.1101\/2021.02.10.21251518"},{"key":"2022010300551048000_2021.12.22.473880v2.23","doi-asserted-by":"crossref","unstructured":"S. Jangra , C. Ye , R. Rathnasinghe , D. Stadlbauer , g. Personalized Virology Initiative study, F. Krammer , V. Simon , L. Martinez-Sobrido , A. Garcia-Sastre , M. Schotsaert , SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe, (2021).","DOI":"10.1016\/S2666-5247(21)00068-9"},{"key":"2022010300551048000_2021.12.22.473880v2.24","doi-asserted-by":"crossref","unstructured":"S. N. Neerukonda , R. Vassell , S. Lusvarghi , R. Wang , F. Echegaray , L. Bentley , A. E. Eakin , K. J. Erlandson , L. C. Katzelnick , C. D. Weiss , W. Wang , SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity. bioRxiv, (2021).","DOI":"10.1101\/2021.11.05.467523"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.12.22.473880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:31:29Z","timestamp":1768444289000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.12.22.473880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1101\/2021.12.22.473880","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1126\/scitranslmed.abn8543","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2021,12,23]]},"subtype":"preprint"}}